Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cohn

Showing results (541-550 of 612) with videos related to

Pageof 62
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 2, 2020
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
British Journal of Cancer|June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group studyL L Wang, R Teshiba, N Ikegaki, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2021
Global monitoring of the impact of the COVID-19 pandemic through online surveys sampled from the Facebook user baseChristina M Astley, Gaurav Tuli, Kimberly A Mc Cord, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2016
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group studyH M Katzenstein, L C Bowman, G M Brodeur, et al.
Cancer|October 5, 2019
Unrealistic parental expectations for cure in poor-prognosis childhood cancerJennifer W Mack, Angel M Cronin, Hajime Uno, et al.
Cancer|December 15, 2023
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey studyErica C Kaye, Jesse Smith, Yiwang Zhou, et al.
Cancer|August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupLarry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.
Pageof 62

Showing results (541-550 of 612) with videos related to

Sort By:
Pageof 62
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 2, 2020
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
British Journal of Cancer|June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group studyL L Wang, R Teshiba, N Ikegaki, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2021
Global monitoring of the impact of the COVID-19 pandemic through online surveys sampled from the Facebook user baseChristina M Astley, Gaurav Tuli, Kimberly A Mc Cord, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2016
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group studyH M Katzenstein, L C Bowman, G M Brodeur, et al.
Cancer|October 5, 2019
Unrealistic parental expectations for cure in poor-prognosis childhood cancerJennifer W Mack, Angel M Cronin, Hajime Uno, et al.
Cancer|December 15, 2023
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey studyErica C Kaye, Jesse Smith, Yiwang Zhou, et al.
Cancer|August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupLarry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.
Pageof 62